|Articles|May 8, 2018
The Missing Link in Amazon’s Healthcare Takeover
Author(s)Michelle Maskaly
John Cervione, managing partner of Blue Fin Group, talks briefly about Amazon’s foray into the healthcare and pharma industries.
Advertisement
John Cervione, managing partner of Blue Fin Group, talks briefly about Amazon’s foray into the healthcare and pharma industries, talks about what they are doing now, and the key element that is missing. His remarks come after a seminar at Asembia’s Specialty Pharmacy Summit in Las Vegas.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
M&A Roundup: McKesson to Acquire Precision Medicine Group, Lundbeck & Eversana Enter AI-Powered Partnership
2
Why Integrated GMP Operating Models Are Reshaping Outsourced Manufacturing
3
Hanmi Pharm Enters $2.3 Billion Licensing Agreement with Genentech for HM17321
4
Beyond Amyloid, Part One (of two): Tau and Microglia Redefine the Alzheimer’s Pipeline
5